Companies / New York / Indaptus Therapeutics

· rebuilt nightly from public records

Signal Sheet

Selling to Indaptus Therapeutics? Who to reach and why now

Indaptus Therapeutics is a publicly listed pharmaceutical preparations company in New York, New York, founded 2021. It raised $2.3M in Jun 2025 and its filings name 15 officers. Everything below links to the record it came from.

Listed company · Pharmaceutical Preparations · New York

The easy button for new customers

Lakewave's AI keeps accounts like this one coming. Your pipeline refills while you sleep.

Every night it scans funding, filings, new officers, hiring, contracts, permits and bids, finds the accounts that fit what you sell, and delivers each with outreach and a pursuit plan. Just need a list? Its AI waterfall builds one with verified, reachable contacts.

SourceNew accounts that match what you offer, added as the signals land. The list never runs dry.
Reach outA first email written from why the account is hot, then a drip sequence that follows up until they reply. Sent from your own mailbox, with every open and reply tracked.
PursueAn AI-written plan built from your value proposition and the customer's compelling event: who to call, what to lead with, and the next step to win it. In early access.
Start your free trial →Tell it what you sell and where. Your list stays yours.

Who to reach

The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names

RoleContactSourceWhy they matter now
Executive OfficerJeffrey A. MecklerSEC filing, Jun 2025Named officer in the filing; part of the buying group
Executive OfficerMichael J NewmanSEC filing, Jun 2025Named officer in the filing; part of the buying group
Executive OfficerNir SassiSEC filing, Jun 2025Named officer in the filing; part of the buying group
Executive OfficerWalt A. LinscottSEC filing, Jun 2025Named officer in the filing; part of the buying group
Executive OfficerRoger J. WaltzmanSEC filing, Jun 2025Named officer in the filing; part of the buying group
Executive OfficerWalt A LinscottSEC filing, Jan 2025Named officer in the filing; part of the buying group
Executive OfficerMichael J. NewmanSEC filing, Jan 2025Named officer in the filing; part of the buying group
Executive OfficerRoger WaltzmanSEC filing, Jan 2025Named officer in the filing; part of the buying group
Chief Technology OfficerRoger J. PomerantzSEC filing, Jun 2025Technology and tooling decisions
Chief Technology OfficerHila KarahSEC filing, Jun 2025Technology and tooling decisions
Chief Technology OfficerAnthony J. MaddalunaSEC filing, Jun 2025Technology and tooling decisions
Chief Technology OfficerWilliam B. HayesSEC filing, Jun 2025Technology and tooling decisions
Chief Technology OfficerMark J. GilbertSEC filing, Jun 2025Technology and tooling decisions
Chief Technology OfficerRobert E. MartellSEC filing, Jun 2025Technology and tooling decisions
Chief Technology OfficerMark J GilbertSEC filing, Jan 2025Technology and tooling decisions
For sellersWhy Indaptus Therapeutics is worth a call this quarterBuy Window: open · major agreement Sep 2026
Sep 2026Sep 2026

Corporate event

Signed a material agreement

Corporate event
Sep 2Sep 2026

New leadership

Officer or director change

New leadership
$2.3M

Raised

Equity raise reported to the SEC, Jun 2025. Money arrives before the spending plan does.

Capital
Track Indaptus Therapeutics with a free trial →Get the next signal the day it is filed or posted.
Email me the next Indaptus Therapeutics signalOne email when it files, raises, hires or posts a role. Watch up to 3 companies free, no password.

Why now

The most recent events first, refreshed every night. Each links to the record it came from.

WhenWhat happenedKindSource
Sep 29, 2026Signed a material agreementCorporate eventSEC filing
Sep 8, 2026Signed a material agreementCorporate eventSEC filing
Sep 2, 2026Officer or director changeNew leadershipSEC filing
Aug 28, 2026Signed a material agreementCorporate eventSEC filing
Aug 28, 2026Signed a material agreementCorporate eventSEC filing
Jun 12, 2025Raised $2.3M in equity from 20 investorsCapitalSEC filing
Jan 16, 2025Raised $2.2M in equity from 16 investorsCapitalSEC filing
Nov 22, 2024Raised $227K in equity from 20 investorsCapitalSEC filing

Reach Indaptus Therapeutics with emails that land

Lakewave finds the right people at Indaptus Therapeutics, checks every address against the mail server before you see it, and drafts a first email for each, which you review and send from your own inbox.

Try it on Indaptus Therapeutics with a free trial →

About Indaptus Therapeutics

HeadquartersNew York, New York, per the filing address
Industry groupPharmaceutical Preparations
Founded2021, DE
OwnershipListed company
Raise history$227K (Nov 2024) · $2.2M (Jan 2025) · $2.3M (Jun 2025)

Similar companies

Private-sector companies in the same industry group and state, ranked by Rising score.

Acurx Pharmaceuticals · 55Pfizer · 16iBio · 11Regeneron Pharmaceuticals · 5Royalty PharmaProPhase LabsSee all 6 with a free trial →

Questions people ask

Did Indaptus Therapeutics raise funding in 2025?

Yes. Indaptus Therapeutics reported a $2.3M equity raise to the SEC on Jun 12, 2025 with 20 investors.

Who runs Indaptus Therapeutics?

The company's SEC filing, Jun 2025 names Jeffrey A. Meckler (Executive Officer) among its officers.

Where is Indaptus Therapeutics headquartered?

New York, New York, per the address on its SEC filing.

Know who is buying before the first callStart your free trial →

Know who is buying before the first call

Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.

Start your free trial

Compiled from public records and refreshed nightly; last updated Nov 16, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.